Piperazine Citrate Worm Tablets

Country: United Kingdom

Language: English

Source: VMD (Veterinary Medicines Directorate)

Active ingredient:

Piperazine Citrate

Available from:

Ayrton Saunders Limited

ATC code:

QP52AH01

INN (International Name):

Piperazine Citrate

Authorization status:

Expired

Summary of Product characteristics

Revised: November 2022
AN: 01984/2022
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF VETERINARY MEDICINAL PRODUCT
Piperazine Citrate Worm Tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Active Ingredient: Piperazine Citrate, 500mg/tablet
3.
PHARMACEUTICAL FORM
Tablet.
4.
PHARMACOLOGICAL PROPERTIES
Summary Presentation of the Active Ingredient
Piperazine Citrate is an anthelmintic of low toxicity with a high
efficiency
against ascarids and some other nematodes.
Pharmacodynamic Properties
Piperazine acts to block neuromuscular transmission in the parasite by
hyperpolarizing the nerve membrane, which leads to flaccid paralysis.
It
also blocks succinate production by the worm. The parasites, paralysed
and depleted of energy, are expelled by peristalsis. It is active
against
the ascarids Toxocara canis, Toxocara cati/ roundworm, Toxascaris
leonine and hookworms.
Pharmacokinetic Properties
Piperazine is rapidly absorbed from the GI tract, and piperazine base
can be detected in the urine as early as 30 minutes after
administration.
The excretion rate is maximal at 1 – 8hr, and excretion is
practically
complete within 24hrs.
ATC Vet Code QP52AH01
5.
CLINICAL PARTICULARS
5.1
TARGET SPECIES
Cat, Dog.
5.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Piperazine Citrate is indicated for the treatment and control of
intestinal
infections/ infestations of dogs and cats, and may be used from 2
weeks of age.
5.3
CONTRA-INDICATIONS
Whilst piperazine salts have few side effects and are of low toxicity,
care should be taken, especially with kittens and puppies, to ensure
that
the
correct
dosage
is
calculated
by
weighing
the
animal
prior
to
Revised: November 2022
AN: 01984/2022
administration of the drug. Animals weighing less than 1.25kg should
be
treated with a suitable anthelmintic licensed for this purpose.
Do not repeat treatment if vomiting occurs shortly after dosing.
Do not administer more than 6 tablets in a single dose. If no vomiting
occurs the remaining dose may be given after 3 hours.
5.4
UNDESIRABLE EFFECTS,